Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

导出原文传递

翻译打印收藏纠错

作者： Kate,Manos ^[1] ; Geoffrey,Chong ^[2] ; Colm,Keane ^[3] ; Sze-Ting,Lee ^[4] ; Charmaine,Smith ^[5] ; Leonid,Churilov ^[6] ; Joseph,McKendrick ^[7] ; William,Renwick ^[8] ; Piers,Blombery ^[9] ; Melinda,Burgess ; Niles Elizabeth,Nelson ; Tineke,Fancourt ; Joanne,Hawking ; Wendi,Lin ; Andrew M.,Scott ; Allison,Barraclough ; Joel,Wight ; Andrew,Grigg ; Chun Yew,Fong ; Eliza A.,Hawkes

作者单位： Fiona Stanley Hospital ^[1] Townsville University Hospital ^[2] Peter MacCallum Cancer Centre ^[3] Olivia Newton John Cancer Research Institute at Austin Health ^[4] Ballarat Regional Integrated Cancer Centre ^[5] Princess Alexandra Hospital ^[6] Melbourne Medical School,University of Melbourne ^[7] Eastern Health ^[8] Western Health ^[9]

发布时间 2023-09-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia

2023年37卷5期

1092-1102页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除